Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 5;60(Supple 2):ii45-ii51.
doi: 10.1093/rheumatology/keaa896.

JAK1 inhibition and inflammatory bowel disease

Clare Harris  1 , J R Fraser Cummings  1
Affiliations
Review

JAK1 inhibition and inflammatory bowel disease

Clare Harris et al. Rheumatology (Oxford). .

Abstract

Primary non-response and secondary loss of response remain a significant issue with the currently available treatment options for a significant proportion of patients with inflammatory bowel disease (IBD). There are multiple unmet needs in the IBD treatment algorithm and new treatment options are required. As our understanding of the pathogenesis of IBD evolves, new therapeutic targets are being identified. The JAK-STAT pathway has been extensively studied. Tofacitinib, a JAK1 inhibitor, is now licensed for use in the induction and maintenance of ulcerative colitis and there are a large number of molecules currently under investigation. These new small molecule drugs (SMDs) will challenge current treatment pathways at a time when clinical therapeutic outcomes are rapidly evolving and becoming more ambitious. This is a review of the current JAK1 inhibitors in IBD including the current evidence from clinical trials.

Keywords: Crohn’s disease; JAK1 inhibitors; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

References

    1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L.. Crohn's disease. Lancet 2017;389:1741–55. - PubMed
    1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF.. Ulcerative colitis. Lancet 2017;389:1756–70. - PMC - PubMed
    1. Kozuch PL, Hanauer SB.. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008;14:354–77. - PMC - PubMed
    1. US Food and Drug Administration. Remicade (Infliximab) Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl...: US Food and Drug Administration; 2013. Contract No.: 3403013 (20 August 2020, date last accessed).
    1. Kennedy NA, Heap GA, Green HD. et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 2019;4:341–53. - PubMed

Publication types

MeSH terms